Pharmaceutical forum is open to any pharmacist who is engaged with industrial practice. Its a platform to share and update your industry related knowledge and skills. Eg: DCGI notifications, D&C Act, Formulation methods and Policy initiatives.
Forum rules: Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
Sun Pharma has received approval from the US health regulator for its non-steroid drug BromSite used to treat inflammation and prevent pain in patients undergoing cataract surgery. One of the company's wholly-owned subsidiaries "has received approval from USFDA for its New Drug Application (NDA) related to BromSite (bromfenac ophthalmic solution) 0.075 percent for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery,"
Sun Pharmaceutical Industries said in a filing to BSE. The drug has been developed by InSite Vision which the company had acquired in November 2015, it added. The company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016, it said. "As per IMS MAT January 2016, the US NSAID ophthalmic market grew by 8 percent, generating approximately USD 400 million in sales and about 4 million prescriptions, providing an attractive market for Sun.
As per the USFDA, NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the US.
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's largest drug maker.